<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="247">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05157932</url>
  </required_header>
  <id_info>
    <org_study_id>20210525-01H</org_study_id>
    <nct_id>NCT05157932</nct_id>
  </id_info>
  <brief_title>An Evaluation of the Talk Test for Exercise Prescription for Home-Based Cardiac Rehabilitation</brief_title>
  <acronym>Talk-Test</acronym>
  <official_title>An Evaluation of the Talk Test as an Effective and Safe Approach for Exercise Prescription for Home-Based Cardiac Rehabilitation: A Pilot RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this pilot RCT are to examine if the Talk Test is an effective and safe&#xD;
      tool as compared with CPET for exercise prescription in patients who have undergone CABG or&#xD;
      PCI and enrolled in a home-based CR program with virtual exercise training monitoring.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Talk Test has been shown to be a valid, practical and inexpensive tool for guiding&#xD;
      exercise training in patients with CAD. The general premise of the Talk Test is that&#xD;
      exercising at or above the ventilatory threshold or lactate threshold does not allow&#xD;
      comfortable, conversational speech and thus serves as a means of estimating the cut point&#xD;
      between moderate and vigorous intensity exercise. The Talk Test can be used to produce&#xD;
      exercise intensities (64 to 95% HR peak i.e. moderate-to-vigorous intensity exercise) within&#xD;
      accepted Canadian Association of Cardiovascular Prevention and Rehabilitation (CACPR)&#xD;
      guidelines for exercise training, to avoid exertional ischemia, and has been shown to be&#xD;
      consistent across various modes of exercise (i.e. walking, jogging, cycling, elliptical&#xD;
      trainer and stair stepper).&#xD;
&#xD;
      There is a critical need to evaluate the effectiveness and safety of using the Talk Test as&#xD;
      the principal method of exercise prescription in patients with CAD who have undergone CABG or&#xD;
      PCI when compared to standard care CPET. Such a trial has wide-scale appeal for CR programs&#xD;
      across Canada and beyond. It will directly and positively impact patient care by reducing the&#xD;
      need for in-person interactions for CPET, of paramount importance during COVID-19 outbreaks,&#xD;
      between patients and CR staff, thus reducing COVID-19 infection risk and concerns of&#xD;
      contracting the virus.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 5, 2022</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>from baseline to follow-up at week 12</time_frame>
    <description>will be measured by the Incremental Shuttle Walk Test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular health indicators - Plasma glucose</measure>
    <time_frame>from baseline to follow-up at week 12</time_frame>
    <description>will be measured by fasting plasma glucose (mmol/L) test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular health indicators - Plasma glucose average</measure>
    <time_frame>from baseline to follow-up at week 12</time_frame>
    <description>will be measured using the glycated hemoglobin A1C (%) test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular health indicators - Lipid profile</measure>
    <time_frame>from baseline to follow-up at week 12</time_frame>
    <description>will be measured using the triglycerides test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular health indicators - Cholesterol HDL</measure>
    <time_frame>from baseline to follow-up at week 12</time_frame>
    <description>will be measured high-density lipoprotein cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular health indicators - Cholesterol LDL</measure>
    <time_frame>from baseline to follow-up at week 12</time_frame>
    <description>will be measured low-density lipoprotein cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Rehab safety</measure>
    <time_frame>from baseline to follow-up at week 12</time_frame>
    <description>meticulously track all mild, moderate, and severe symptoms and adverse events throughout this study. Symptoms may include tightness in chest, leg tightness/pain, dizziness, lightheaded, foot cramping, and heart palpitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VO2peak</measure>
    <time_frame>at baseline</time_frame>
    <description>will be measured using a gold standard symptom-limited CPET on an electronically braked cycle ergometer (alternatively it will be administered on a treadmill or another aerobic equipment). Gas exchange (VO2 in mL/kg/min) and heart rate will be monitored continuously. The highest 20-s interval average of VO2 and HR will be considered the peak VO2 and HR values.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exercise prescription compliance</measure>
    <time_frame>from baseline to follow-up at week 12</time_frame>
    <description>Talk Test group: HR will be measured during exercise training using the Polar A370 device. Following each exercise session, participants will record on a Talk Test log if: (1) singing was possible, (2) comfortable conversation, but not singing was possible, or (3) comfortable conversation was not possible. These responses will be coded as &quot;does not comply&quot;, &quot;complies&quot; and &quot;exceeds&quot;. CPET group: HR will be measured during exercise training using the Polar A370 device. Where participants exercise below, within or above the prescribed HR ranges (64 to 95% HR peak), they will be coded as &quot;does not comply&quot;, &quot;complies&quot; and &quot;exceeds&quot;. All participants will wear Polar A370 devices during their exercise training sessions. Exercise HRs will be compared between the Talk Test and CPET groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiometabolic health indicators - BMI</measure>
    <time_frame>from baseline to follow-up at week 12</time_frame>
    <description>Height (cm) and body mass (kg) will be measured to compute body mass index (kg/m2)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiometabolic health indicators - Body composition</measure>
    <time_frame>from baseline to follow-up at week 12</time_frame>
    <description>Body composition will be measured using Fat mass (%) and fat-free mass (%), using bioelectrical impedance analysis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiometabolic health indicators - Cardiometabolic Risk</measure>
    <time_frame>from baseline to follow-up at week 12</time_frame>
    <description>will be measured using waist circumference (cm) and will be measured using standardized procedures.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiometabolic health indicators - Blood pressure</measure>
    <time_frame>from baseline to follow-up at week 12</time_frame>
    <description>Resting Systolic (mmHg) and Diastolic (mmHg) blood pressure will be measured in a seated position after a 5-minute rest period on the right arm using an automated, BP monitor (BPTru) that measures 6 times (the first will be discarded and an average of the last 5 measurements will be used for statistical analyses) at 2-minute intervals.</description>
  </other_outcome>
  <other_outcome>
    <measure>Gender</measure>
    <time_frame>from baseline to follow-up at week 12</time_frame>
    <description>gender and its effect will be assessed during cardiac rehabilitation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Talk Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Virtual Cardiac Rehab + Exercise prescription based on the Talk test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiopulmonary Exercise Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Virtual Cardiac Rehab + Exercise prescription based on the CPET results.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Talk test prescription</intervention_name>
    <description>Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on the Talk test method.</description>
    <arm_group_label>Talk Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CPET prescription</intervention_name>
    <description>Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on their CPET results completed at baseline</description>
    <arm_group_label>Cardiopulmonary Exercise Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  recently underwent PCI or CABG (at least 4 weeks but less than 12 weeks post-event or&#xD;
             procedure);&#xD;
&#xD;
          -  able to perform a CPET;&#xD;
&#xD;
          -  at least 40 years of age;&#xD;
&#xD;
          -  access to MyChart; and,&#xD;
&#xD;
          -  access to email and the internet&#xD;
&#xD;
          -  access to a cellphone with broadband internet (4G, LTE, 5G).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  currently participating in a virtual or on-site CR program;&#xD;
&#xD;
          -  ventricular ejection fraction â‰¤45%;&#xD;
&#xD;
          -  unstable angina or established diagnosis of chronic obstructive pulmonary disease,&#xD;
             severe mitral or aortic stenosis, or hypertrophic obstructive cardiomyopathy;&#xD;
&#xD;
          -  unable to return for 12-week follow-up visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Pipe, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Reed, PhD</last_name>
    <phone>6136967392</phone>
    <email>jreed@ottawaheart.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matheus Mistura</last_name>
    <phone>6136967000</phone>
    <phone_ext>15944</phone_ext>
    <email>mmistura@ottawaheart.ca</email>
  </overall_contact_backup>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>October 8, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary artery disease</keyword>
  <keyword>Talk test</keyword>
  <keyword>Cardiopulmonary Exercise test</keyword>
  <keyword>Cardiac rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>it is not yet known if there will be a plan to make IPD available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

